GlassScriptPhysician profile
Ali A Zaidi
NPI 1417006479
$7,999.46
in general payments reported to CMS, 2019-2025
30 companies · $919 in 2025
The $919 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $540 · 2021: $369 · 2022: $2,029 · 2023: $1,166 · 2024: $1,421 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.18 | 2022-2025 | Durysta, Lumigan |
| Genentech USA, INC. | $1,080.00 | 2019-2025 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $911.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $527.46 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $413.19 | 2020-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $389.48 | 2019-2021 | |
| Oyster Point Pharma, INC. | $376.95 | 2022-2025 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $373.49 | 2023-2025 | Izervay |
| Alcon Vision LLC | $358.28 | 2022-2025 | Rocklatan, Eysuvis |
| Biotissue Holdings INC. | $282.46 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $257.80 | 2022-2024 | Syfovre |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Bausch & Lomb Americas INC. | $196.71 | 2022-2025 | Miebo, Vyzulta, Xipere |
| E.R. Squibb & Sons, L.L.C. | $193.43 | 2019 | |
| Gilead Sciences, INC. | $131.57 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $99.84 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $95.53 | 2019-2022 | |
| Genentech, INC. | $86.80 | 2019-2024 | Vabysmo, Susvimo |
| Aerie Pharmaceuticals, INC. | $81.94 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $81.75 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.29 | 2019-2021 | |
| Ethicon US, LLC | $68.16 | 2019 | |
| Eyepoint US, INC. | $34.75 | 2022 | |
| Sight Sciences, INC. | $34.47 | 2021-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $34.39 | 2024 | Xdemvy |
| Alimera Sciences, INC. | $34.13 | 2019 | |
| Horizon Therapeutics Plc | $27.63 | 2023 | Tepezza |
| Amgen INC. | $25.06 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $18.41 | 2019 | |
| Ocular Therapeutix, INC. | $17.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Zaidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.